PMU-Autor/inn/en
Nardone RaffaeleAbstract
AHA is caused by autoantibodies against factor VIII (FVIII). Immunosuppressive treatment (IST) results in remission of disease in 60-80% of patients over a period of days to months. IST is associated with frequent adverse events, including infections as a leading cause of death. Predictors of time to remission could help guiding IST intensity, but have not been established. We analyzed prognostic factors in 102 prospectively enrolled patients treated with a uniform IST protocol. Partial remission (PR, defined as no active bleeding, FVIII restored >50 IU/dl, hemostatic treatment stopped >24 h) was achieved by 83% of patients after a median of 31 days (range 7-362). Patients with baseline FVIII <1 IU/dl achieved PR less often and later (77%, 43 days) than patients with ≥1 IU/dl (89%, 24 days). After adjustment for other baseline characteristics, low FVIII remained associated with a lower rate of PR (hazard ratio 0.52, 95% confidence interval 0.33-0.81, p<0.01). In contrast, PR achieved on steroids alone within ≤21 days was more common in patients with FVIII ≥1 IU/dl and inhibitor concentration <20 BU/ml (odds ratio 11.2, p<0.0001). Low FVIII was also associated with a lower rate of complete remission and decreased survival. In conclusion, presenting FVIII and inhibitor concentration are potentially useful to tailor IST in AHA.
Find related publications in this database (Keywords)
Epilepsy